Shares of Cassava Sciences Inc. dropped more than 12% in the ... The company said it cooperated with the SEC’s investigation and “implemented remedial measures.” The company also said ...

26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (“Cassava” or the ... with the U.S. Securities and Exchange Commission (“SEC”) of negligence-based disclosure charges that resolve ...

Cassava Sciences ( (SAVA)) has provided an announcement ... Amid these advancements, Cassava settled with the SEC, paying a $40 million penalty for inaccurately disclosed information, allowing ...

Cassava Sciences is moving forward with Phase III trials after paying $40m to settle an SEC case alleging misleading data from its Phase IIb trial of simufilam. The US Securities and Exchange ...

Cassava Sciences (NASDAQ:SAVA ... citing a settlement the company recently reached with the SEC. With only Hold ratings from analysts, the fortunes of the Austin, Texas-based biotech have reversed ...

Cassava Sciences faced a $40 million penalty to focus on Simufilam's development following SEC charges over misleading trial data. Cassava Sciences completed ReTHINK Phase 3 trial with 804 ...

Bearish flow noted in Cassava Sciences (SAVA) with 2,978 puts trading, or 1.3x expected. Most active are Nov-24 27 puts and Dec-24 10 puts, ...

Bullish option flow detected in Cassava Sciences (SAVA) with 4,141 calls trading, 1.2x expected, and implied vol increasing almost 14 points to ...

Cassava Sciences and two former executives will pay ... violating reporting provisions of the federal securities laws, the SEC said. Without admitting or denying the allegations Cassava, Barbier ...

Last month, Cassava Sciences Inc. (NASDAQ:SAVA) agreed to pay over $40 million to resolve SEC charges over misleading statements related to a Phase 2 trial of the company’s controversial ...